Treatment News : New Possibility for Some Heavily Treatment Experienced: Add Reyataz or Invirase

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » February 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


February 22, 2011

New Possibility for Some Heavily Treatment Experienced: Add Reyataz or Invirase

A drug-resistance mutation in HIV’s protease gene may actually be advantageous and make the virus more sensitive to antiretroviral drug regimens containing either Reyataz (atazanavir) or Invirase (saquinavir), according to a paper published online ahead of print in AIDS Research and Therapy.  

Typically, once a person’s HIV acquires enough mutations to resist an antiretroviral (ARV), the virus may also become partially or fully resistant to other ARVs in the same drug class, even if those medications haven’t been used. This is called cross-resistance.

Occasionally, however, resistance to one drug can actually increase the effectiveness of another. For example, if the M184V mutation in HIV’s reverse transcriptase gene develops while a person is being treated with either Epivir (lamivudine) or Emtriva (emtricitabine), the anti-HIV activity of Retrovir (zidovudine) becomes more pronounced.

Until recently, it was assumed that the L76V mutation in HIV’s protease gene, which can arise during therapy with a protease inhibitor, can make other protease inhibitors less active against the virus. This assumption was based on test-tube studies that looked at the genes of this particular mutation. Since then, however, lab studies have hinted that this mutation, rather than reducing the effectiveness, might actually increase the effectiveness of two protease inhibitors: Reyataz and Invirase.

To test this theory, Frank Weismann, MD, from the HIV and Hepatitis Research Group at the Praxen Zentrum Blodelstrasse in Aachen, Germany, and his colleagues looked at the medical records of 46 heavily treatment experienced individuals who received care at their network of clinics between 1999 and 2009. All the study participants had the L76V protease mutation at the start of the study, in this case caused by either Kaletra (lopinavir plus ritonavir) or Lexiva (fosamprenavir), or an earlier formulation of Lexiva called Agenerase (amprenavir).

The participants were split into three groups based on how they changed their regimens. One group (group A) switched up their entire regimen, going off Kaletra, Lexiva or Agenerase altogether. The other two groups stayed on those drugs, but added either Reyataz or Invirase (group B), or they added drugs other than Reyataz or Invirase (group C).

Over the course of two years of follow-up the difference between the three groups, in terms of viral suppression, was striking. Initially, 50 percent of those in group A and 67 percent of those in group B were able to get their virus below 50 copies. None of the people in group C did so.

Over time, however, the ability to remain virally suppressed diverged widely between groups A and B. After 96 weeks, 67 percent of those in group B continued to have full HIV suppression, compared with only 17 percent of those in group A. This was true despite the fact that genotypic resistance testing predicted that people in group B would actually have fewer active drugs in their regimen than those in group A.

Weismann and his coauthors caution that their results are preliminary. What’s more, there is evidence that the increased susceptibility to Reyataz or Invirase can be reduced if a second mutation, called the L90M, is also present. As Invirase can cause the L90M mutation, it is possible that Reyataz would be safer to use.

Nevertheless, the authors conclude: “In case of L76V-occurrence, [Reyataz] and/or [Invirase] may represent encouraging options for patients in deep salvage situations.”

Search: Reyataz, atazanavir, Invirase, saquinavir, Lexiva, fosamprenavir, Agenerase, amprenavir, Kaletra, lopinavir, ritonavir, Frank Weismann, L76V, L90M, M184V

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.